Endometriosis ~ Abdominal Pain ~ Endo ~ Scar Tissue ~ Adhesions ~ Infertility ~ Hysterectomy

Thursday, February 08, 2007

Examine the Role Angiogenesis Inhibitors Have in Cancer, Dermatology, Ophthalmology & Rheumatology

DUBLIN, Ireland--(BUSINESS WIRE)--Feb 7, 2007 - Research and Markets (http://www.researchandmarkets.com/reports/c49924) has announced the addition of Angiogenesis Modulators - A Market Insight Report to their offering.
This market insight report on Angiogenesis Modulators studies the impact of Inhibitors and Stimulators on various diseases. The study focuses on major angiogenesis inhibitors and their role in diseases such as cancer, dermatology, ophthalmology, rheumatology and other angiogenesis based diseases including endometriosis and inflammatory diseases. The emphasis is also given on major angiogenesis stimulators and their role in diseases such as cardiovascular disorders including ischemia, congestive heart failure, coronary artery disease, myocardial infarction and peripheral vascular disease and chronic wound care. The study provides global market analysis for angiogenesis therapeutic products by the above angiogenesis modulators and also by the disease areas such as cancer, cardiovascular disorders and other angiogenesis based diseases. The study includes estimates and projections for the total global angiogenesis therapeutic products market. Projections and estimates are also illustrated by geographic regions encompassing United States, Europe, Asia-Pacific and Rest of World. Business profiles of 34 major companies are discussed in the report. The report serves as a guide to global angiogenesis industry covering 334 companies engaged in angiogenesis research, testing and supply of products and services. Major Contract Research Organizations and Universities serving angiogenesis industry are also covered in the Corporate Directory section of this report. Information related product developments, partnerships, collaborations, and mergers and acquisitions are also covered in the report featuring 92 graphically represented exclusive exhibits. -0-
http://www.pharmalive.com/News/index.cfm?articleid=413193&categoryid=15

No comments: